Technology Networks spoke to the most productive researcher in spatial transcriptomics, Professor Joakim Lundeberg, about the ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th.The company reported ($0.40) earnings per share for the quarter, missing the ...

Finally, UBS Group dropped their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th.

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

An international team of scientists from Australia and China has unveiled the first chromosome-scale genome of a wild barley ...

Mindmonia Why Meditating in Nature Is 10x More Powerful Than Doing It Indoors Posted: March 9, 2025 | Last updated: March 9, 2025 Immerse yourself in the tranquility of nature while meditating ...